Overview

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is the first study in cutaneous lupus erythematosus subjects to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CC-11050.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Celgene Corporation